Salute e Benessere

Nordic Nanovector announces agreement to acquire Thor Medical, an emerging…

Ludvik Sandnes, Nordic Nanovector's Interim CEO & CFO, commented: "Given the complementary focus and expertise in our two companies, the Nordic Nanovector Board and I believe the proposed acquisition of Thor Medical represents a compelling option for Nordic Nanovector and its shareholders. There is increasing interest in the development of radionuclide-based anti-cancer therapies, and the combined company will have a significant opportunity to address this growing market." Ludvik…
PR Newswire
06/06/2023

Digital Twins in Healthcare Market worth $21.1 billion | MarketsandMarkets

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=74014375 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=74014375 Browse in-depth TOC on "Digital Twins in Healthcare Market" 110 - Tables 40 - Figures 180 - Pages Digital Twins in Healthcare Market Scope: The research and Academia segment is expected to register a substantial growth in the digital twins in healthcare market, by end...
PR Newswire
06/06/2023

Information on the Total Number of Voting Rights (Denominator) following…

Regulated Information - Denominator Atlas Special Opportunities, LLChas converted 8convertible bonds in Oxurion resulting in a EUR 200 ,000capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5billion.Leuven, BELGIUM ,Boston, MA, US–...
Nasdaq GlobeNewswire
06/06/2023

Active Pharmaceutical Ingredients and High Potency API Industry Banks on API…

CMOs and CDMOs have furthered their focus on HPAPI manufacturing and development to keep up with the drug demand for antibody drug conjugates and oncology. To illustrate, in March 2022, Lonza announced laboratory expansion at its API manufacturing site in China. It will underpin the early-phase highly-potent API manufacturing capabilities and help the company boost clinical trials in oncology. The global high potency API market size stood at USD 23.60 billion in 2021 and is slated to depict a…
PR Newswire
06/06/2023

IPSEN - Buy-back programme - Art 5 of MAR - Week 22 - 2023

Aggregatedpresentationbydayandbymarket NameofissuerIdentificationcodeof issuer(Legal Entity Identifier) Day of transaction Identificationcodeof financialinstrumentAggregated daily volume(innumber of shares) Dailyweightedaveragepriceof the purchased shares * Market(MICCode) IPSEN549300M6SGDPB4Z94P1101/06/2023FR0010259150284111,21AQEUIPSEN549300M6SGDPB4Z94P11...
Nasdaq GlobeNewswire
06/06/2023

Impressive Expansion Expected for Biosafety Cabinets Market Amidst the COVID-19…

The recent outbreak of the infectious disease COVID-19 has had a profound impact worldwide, prompting heightened awareness of hygiene practices and safety measures. By 2021, the infection had affected over 663 million individuals globally, resulting in the tragic loss of over 6.7 million lives. This alarming situation has underscored the critical need for safety precautions and the establishment of facilities capable of handling testing samples and facilitating the production and distribution of…
PR Newswire
06/06/2023

Transactions in connection with share buy-back program

Company announcement no. 24 - 236 June 2023 Transactions in connection with share buy-back program On 8 May 2023 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company announcement no. 17 - 23. The program will be executed in accordance with the principles of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbor rules...
Nasdaq GlobeNewswire
06/06/2023

CDKL5 Deficiency Disorder Market to Witness Upsurge in Growth, Assesses…

Key Takeaways from the CDKL5 Deficiency Disorder Market Report Key Takeaways from the CDKL5 Deficiency Disorder Market Report Discover which therapies are expected to grab the major CDKL5 deficiency disorder market share @CDKL5 Deficiency Disorder Market Report CDKL5 Deficiency Disorder Overview CDKL5 deficiency disorder is a rare form of developmental epileptic encephalopathy (DEE) caused by alterations in the CDKL5 gene. CDD has been designated as a DEE since the genetic...
PR Newswire
06/06/2023

The Medical Tubing Market Is Anticipated To Reach USD 13570 Million By 2029…

Major Factors Driving The Growth Of The Medical Tubing Market Major Factors Driving The Growth Of The Medical Tubing Market The demand for minimally invasive operations, the rising elderly population, and developments in medical technology have all contributed to the Medical Tubing Market growth. rising healthcare costs, an increase in the prevalence of chronic diseases, and stricter regulatory requirements are expected to further fuel the Medical Tubing Market growth. Browse The...
PR Newswire
06/06/2023

Donatella Versace Announces $300,000 Fundraising Match for Elton John AIDS…

This donation will specifically support the Foundation's efforts to fund programs that enhance access to health resources like HIV testing and compassionate care, and fight discriminatory laws restricting the rights of LGBTQ+ people around the world. This donation will specifically support the Foundation's efforts to fund programs that enhance access to health resources like HIV testing and compassionate care, and fight discriminatory laws restricting the rights of LGBTQ+ people around…
PR Newswire
06/06/2023

OKYO Pharma Announces Randomized Segment Now Underway in Phase 2 Clinical Trial…

Trial designed with a two-week run-in period to reduce the well-known placebo effect in trials involving pain componentTop-line data from trial anticipated in Q4, 2023 LONDON and NEW YORK, June06, 2023(GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar market, is pleased to announce that patients are now...
Nasdaq GlobeNewswire
06/06/2023

Mural Health and ClinOne Partner to Maximize Patient Experience While Minimizing…

Both companies are using technology to help sponsors overcome the stubborn challenges of drug development, including poor recruitment and retention, by focusing product design on the participant (the end-user). Both companies are also committed to reducing the administrative burden that clinical research sites can experience when sponsors require multiple technology platforms. Both companies are using technology to help sponsors overcome the stubborn challenges of drug development, including...
PR Newswire
06/06/2023

GrapheneDx, General Graphene Corp and Sapphiros Enter Into Strategic Partnership…

"This strategic partnership highlights each partner's core competencies, and will allow GrapheneDx to bring affordable, accurate and timely diagnostics to patients around the world," said Mike Musgnug, CEO of GrapheneDx. "We are thrilled to be partnering with General Graphene and Sapphiros to rapidly scale and commercialize our technology by employing best-in-class tools, processes and know-how." "This strategic partnership highlights each partner's core competencies…
PR Newswire
06/06/2023

Colorcon, Inc. Invests in a New Film Coating Manufacturing Plant in Malaysia

According to CPHI's 2022 Global Survey, the ASEAN pharmaceutical manufacturing industry will grow by 12.8% annually over 2021-2027 driven by increasing prevalence of chronic ailments, growing geriatric population, high investment in research and development, and increasing per capita healthcare expenditure. Simon Tasker, CEO, Colorcon Inc. explains: "This investment strengthens our strategy to position Colorcon facilities close to our customers and support the projected growth...
PR Newswire
06/06/2023

Sai Life Sciences reaffirms commitment to Sustainability, charts out SDGs to be…

Contract Research, Development & Manufacturing Organization (CRO-CDMO), announced its renewedSustainable Development Goals (SDG)charting out the roadmap to achieve specific environmental, social and governance (ESG) targets by the financial year ending March 31, 2027. Making the announcement,Krishna Kanumuri, CEO & Managing Director, Sai Life Sciences, said, “Our renewed Sustainable Development Goals reflect a coming of age of our Sustainability journey. The learnings...
Nasdaq GlobeNewswire
06/06/2023

Pediatric Dental Crown Market Analysis 2023-2032: Market Driver, Key Trends…

The pediatric dental crown market is anticipated to rise, as tooth decay and periodontal illnesses become more commonplace. For example, in 2022, the Oral Health Foundation (OHF) and Colgate-Palmolive Dental Caries Awareness Survey indicated that 84% of all adults in the UK belong to groups that put them at higher risk of the disease, with more than 45 million British adults at an increased risk of tooth decay. Therefore, the increase in the prevalence of tooth decay and periodontal diseases is…
PR Newswire
06/06/2023

Piramal Critical Care Appoints Jeffrey Hampton as President & Chief Operating…

Mr. Hampton has also worked with several leading pharmaceutical companies, including Osmotica Pharmaceuticals, Dabur Pharma and IVAX Pharmaceuticals. Mr. Hampton has also worked with several leading pharmaceutical companies, including Osmotica Pharmaceuticals, Dabur Pharma and IVAX Pharmaceuticals. Peter DeYoung, CEO, Global Pharma, Piramal PharmaLimited,said, "I welcome Jeff to Piramal Critical Care and wish him all the success in his new role. His experience across the domains of...
PR Newswire
06/06/2023

Cell and Gene Therapy CDMO Market Soars to US$ 18.6 billion, Fueling…

Cell and gene therapies (CAGT) are used in treating various diseases like heart disease, cancer, diabetes, neurological disorders, and infectious diseases. CAGT has potential for addressing the root cause of genetic and acquired diseases and provides concepts and techniques that can be used in reproductive potential and remodeling, and gene regulation. Cell and gene therapies (CAGT) are used in treating various diseases like heart disease, cancer, diabetes, neurological disorders, and infectious…
PR Newswire
06/06/2023

KOBAYASHI LAUNCHES KOOL 'N' SOOTHE NIGHT COOLING SPRAY TO HELP GIVE MORE…

The L-menthol formula provides a cooling sensation you sweat, keeping you comfortably cool with minimum effort. This is a brand-new and innovative way for UK residents to stay cool during the summer months. The L-menthol formula provides a cooling sensation you sweat, keeping you comfortably cool with minimum effort. This is a brand-new and innovative way for UK residents to stay cool during the summer months. Kool 'n' Soothe Night Cooling Spray will initially be available for purchase on...
PR Newswire
06/06/2023

Noted Vaccine Researcher Thomas P. Monath Awarded Sabin's Gold Medal; Cameroon…

thAlbert B. Sabin Gold Medal Award to Thomas P. Monath, MD, and its Rising Star Award to Sangwe Clovis Nchinjoh, MD, MPH, in a ceremony at Washington D.C.'s National Academy of Sciences building. Dr. Monath was selected for the Gold Medal for his more than four decades of commitment to advancing knowledge of arboviruses and vaccine research and development (R&D) that contributed to the development of several innovative vaccines including those for Ebola Zaire, smallpox, dengue,...
Nasdaq GlobeNewswire
06/06/2023

Alkermes Announces Final Award in Janssen Pharmaceutica Arbitration and Provides…

DUBLIN, June 6, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that on May 31, 2023 it received a final award (the Final Award) from the arbitral tribunal (the Tribunal) in its arbitration proceedings with Janssen Pharmaceutica N.V. (Janssen), a subsidiary of Johnson & Johnson, in respect of two license agreements. In connection with the Final Award, the company raised its financial expectations for 2023 by approximately $425 million, which includes back royalties of…
PR Newswire
06/06/2023

Novo Nordisk A/S – Share repurchase programme

Bagsværd , Denmark, 6June 2023– On 9 May 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 30 billion to be executed during a 12-month period beginning 1 February 2023. Under the...
Nasdaq GlobeNewswire
06/06/2023

Reporting of transactions made by persons discharging managerial…

Company announcement no. 23 - 23 6 June 2023 Reporting of transactions made by persons discharging managerial responsibilities, and persons closely associated with them, in NTG's shares In accordance with section 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation), NTG Nordic Transport Group A/S (“NTG”), CVR no. 12546106, hereby announces receipt of the following notification from persons...
Nasdaq GlobeNewswire
06/06/2023

GLOBAL PHARMACEUTICAL LEADER SETS SIGHT ON SUSTAINABLE FUTURE FOR THE SECTOR BY…

Pharmanovia has made the pledge as it revealed the significant progress made towards achieving its ambitious science-backed ESG initiatives in its new Sustainability Report. Its industry-leading air-to-sea pilot scheme, which focused on its Spain-to-Australia freight route, cut an estimated 470,000kg in potential CO2 emissions in 2022 - reducing Scope 3 upstream transport emissions by 18%. Pharmanovia has made the pledge as it revealed the significant progress made towards achieving its...
PR Newswire
06/06/2023
Altri  Comunicati